February 24, 2022

Whom It May Concern
Company:
Representative:KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:

Telephone:

Yoshinori Tanifuji
Director, Management Strategy &Planning Division Corporate Planning+81-3-3525-4707

Construction of the Takaoka New Plant by a Subsidiary Company
KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Chiyoda-ku, Tokyo;
Representative Director, President and Chief Executive Officer Michiro Ohnota, “GroupFacilities”), which is a subsidiary of KYORIN Holdings, Inc., decided to build the Takaoka New
Plant at Takaoka City, Toyama Prefecture where Group Facilities owns a land.
Under the KYORIN Pharmaceutical Group's long-term vision "HOPE100 (FY 2010-2023)",
Group Facilities is "building a competitive group production system that supplies high-quality
products stably and at low cost" as its strategic priority.
In the medium-term management plan "HOPE100 -Stage 2- (FY 2016-2019)", KYORIN
Holdings set forth the priority strategy “Reform cost structure by group optimization” andintegrated three factories (Noshiro Plant: Noshiro City, Akita Prefecture, Shiga Plant: Koka
City, Shiga Prefecture, Inami Plant: Nanto City, Toyama Prefecture) into Group Facilities inApril 2018, and achieved the initial goal of cost reduction by leveling the factory utilization andefficiently utilizing assets.
In the current medium-term management plan "HOPE100 -Stage 3- (FY 2020-2023)",KYORIN Holdings set forth the priority strategy "Improve cost competitiveness", and isworking on establishing manufacturing system that realizes stable supply of new drugs andgeneric drugs and low cost.
Under such circumstances, as the production of drugs increased, it became necessary tostrengthen the supply capacity of Group Facilities, so KYORIN Holdings decided to construct
the Takaoka Plant.
The Inami Plant, which mainly manufactures generic drugs, will be transferred to theTakaoka Plant because it is difficult to expand facilities and add equipment, and it is aging asa whole.
The Takaoka Plant will have a production capacity of approximately 2 billion tablets, and will be afacility that can further improve GMP (Good Manufacturing Practice). In addition, it will achieve stablesupply and low-cost production by saving labor in various operations and improving manufacturingefficiency.
In terms of the environment, Group Facilities will not only design the Takaoka Plant to significantlyreduce CO2 emissions compared to the current plants, but also promote reducing environmental burden
by actively utilizing clean energy such as liquefied natural gas (LNG) and renewable energy such ashydroelectric power generation.
Under the corporate philosophy “KYORIN will continue fulfill its mission of cherishing life andbenefiting society by contributing to better health”, KYORIN Group will continue to work on the stablesupply of high-quality products.

【Outline of the Takaoka Plant】
Location：IC Park 8, Takaoka-City, Toyama Prefecture

Site Area：42,457㎡

Building：3 Floors, Building area about 7,262㎡, Total floor area about 21,091㎡

Groundbreaking：August 2022 (Planned)
Completion：October 2023 (Planned)

Operation：April 2024 (Planned)

Investment：About 10 billion yen(Exterior image of the Takaoka Plant)